TLR-MyD88信号通路在系统性红斑狼疮中的研究进展
Research Progress on TLR-MyD88 Signaling Pathway in Systemic Lupus Erythematosus
DOI: 10.12677/jcpm.2024.34214, PDF,    科研立项经费支持
作者: 薄 静：济宁医学院临床医学院，山东 济宁；邵 莉：山东省第三人民医院风湿免疫科，山东 济南；李 健, 宋 芹*：济宁医学院附属医院风湿免疫科，山东 济宁
关键词: 系统性红斑狼疮；TLR/MyD88信号通路；免疫细胞；治疗靶点；Systemic Lupus Erythematosus； TLR/MyD88 Signaling Pathway； Immune Cells； Therapeutic Targets
摘要: 系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种慢性炎症性自身免疫性疾病，可影响多个器官，包括皮肤、关节、中枢神经系统和肾脏等，其发病因素包括环境、免疫和激素因素以及遗传易感性等。TLR/MyD88信号通路是调控先天免疫反应和相关的炎症反应的重要通路之一，参与SLE疾病的发生发展。本文总结了TLR/MyD88通路的构成、激活途径，重点介绍了该信号通路在SLE中在免疫细胞中的相关机制，并总结了近年来针对TLR和MyD88的拮抗剂及其潜在的临床应用。
Abstract: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that can affect multiple organs, including the skin, joints, central nervous system, and kidneys. The pathogenic factors include environmental, immune, and hormonal factors, as well as genetic susceptibility. The TLR/MyD88 signaling pathway is one of the important pathways that regulate innate immune responses and related inflammatory responses, and is involved in the occurrence and development of systemic lupus erythematosus (SLE). This article summarizes the composition and activation pathways of the TLR/MyD88 pathway, focusing on the relevant mechanisms of this signaling pathway in immune cells in SLE, and summarizes the antagonists against TLR and MyD88 in recent years and their potential clinical applications.
文章引用：薄静, 邵莉, 李健, 宋芹. TLR-MyD88信号通路在系统性红斑狼疮中的研究进展[J]. 临床个性化医学, 2024, 3(4): 1497-1503. https://doi.org/10.12677/jcpm.2024.34214

参考文献

[1] Stull, C., Sprow, G. and Werth, V.P. (2022) Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist. The Journal of Rheumatology, 50, 27-35. [Google Scholar] [CrossRef] [PubMed]
[2] Liu, M., Kang, W., Hu, Z., Wang, C. and Zhang, Y. (2023) Targeting MyD88: Therapeutic Mechanisms and Potential Applications of the Specific Inhibitor St2825. Inflammation Research, 72, 2023-2036. [Google Scholar] [CrossRef] [PubMed]
[3] Liu, M., Hu, Z., Wang, C. and Zhang, Y. (2023) The TLR/MyD88 Signalling Cascade in Inflammation and Gastric Cancer: The Immune Regulatory Network of Helicobacter pylori. Journal of Molecular Medicine, 101, 767-781. [Google Scholar] [CrossRef] [PubMed]
[4] Medzhitov, R., Preston-Hurlburt, P. and Janeway, C.A. (1997) A Human Homologue of the Drosophila Toll Protein Signals Activation of Adaptive Immunity. Nature, 388, 394-397. [Google Scholar] [CrossRef] [PubMed]
[5] Balka, K.R. and De Nardo, D. (2018) Understanding Early TLR Signaling through the Myddosome. Journal of Leukocyte Biology, 105, 339-351. [Google Scholar] [CrossRef] [PubMed]
[6] Duan, T., Du, Y., Xing, C., Wang, H.Y. and Wang, R. (2022) Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. Frontiers in Immunology, 13, Article ID: 812774. [Google Scholar] [CrossRef] [PubMed]
[7] Kalliolias, G.D., Basdra, E.K. and Papavassiliou, A.G. (2024) Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update. Biomedicines, 12, Article No. 138. [Google Scholar] [CrossRef] [PubMed]
[8] Lord, K.A., Hoffman-Liebermann, B. and Liebermann, D.A. (1990) Nucleotide Sequence and Expression of a cDNA Encoding MyD88, a Novel Myeloid Differentiation Primary Response Gene Induced by IL6. Oncogene, 5, 1095-1097.
[9] Muzio, M., Ni, J., Feng, P., et al. (2013) Pillars Article: IRAK (Pelle) Family Member IRAK-2 and MyD88 as Proximal Mediators of IL-1 Signaling. Science. 1997. 278: 1612-1615. The Journal of Immunology, 190, 16-19.
[10] Wesche, H., Henzel, W.J., Shillinglaw, W., et al. (2013) Pillars Article: MyD88: An Adapter That Recruits IRAK to the IL-1 Receptor Complex. Immunity. 1997. 7: 837-847. The Journal of Immunology, 190, 5-15.
[11] Dunne, A. and O’Neill, L.A.J. (2003) The Interleukin-1 Receptor/Toll-Like Receptor Superfamily: Signal Transduction during Inflammation and Host Defense. Science’s STKE, 2003, e3. [Google Scholar] [CrossRef] [PubMed]
[12] Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C., Ghosh, S., et al. (1998) MyD88 Is an Adaptor Protein in the hToll/IL-1 Receptor Family Signaling Pathways. Molecular Cell, 2, 253-258. [Google Scholar] [CrossRef] [PubMed]
[13] Saikh, K.U. (2021) MyD88 and beyond: A Perspective on MyD88-Targeted Therapeutic Approach for Modulation of Host Immunity. Immunologic Research, 69, 117-128. [Google Scholar] [CrossRef] [PubMed]
[14] Iwasaki, A. and Medzhitov, R. (2004) Toll-Like Receptor Control of the Adaptive Immune Responses. Nature Immunology, 5, 987-995. [Google Scholar] [CrossRef] [PubMed]
[15] Săsăran, M.O., Meliț, L.E. and Dobru, E.D. (2021) MicroRNA Modulation of Host Immune Response and Inflammation Triggered by Helicobacter pylori. International Journal of Molecular Sciences, 22, Article No. 1406. [Google Scholar] [CrossRef] [PubMed]
[16] Takeda, K., Kaisho, T. and Akira, S. (2003) Toll-Like Receptors. Annual Review of Immunology, 21, 335-376. [Google Scholar] [CrossRef] [PubMed]
[17] Fairhurst, A., Wandstrat, A.E. and Wakeland, E.K. (2006) Systemic Lupus Erythematosus: Multiple Immunological Phenotypes in a Complex Genetic Disease. In: Advances in Immunology, Elsevier, 1-69. [Google Scholar] [CrossRef] [PubMed]
[18] Hamilton, J.A., Hsu, H. and Mountz, J.D. (2019) Autoreactive B Cells in SLE, Villains or Innocent Bystanders? Immunological Reviews, 292, 120-138. [Google Scholar] [CrossRef] [PubMed]
[19] Tipton, C.M., Hom, J.R., Fucile, C.F., Rosenberg, A.F. and Sanz, I. (2018) Understanding B‐Cell Activation and Autoantibody Repertoire Selection in Systemic Lupus Erythematosus: A B‐Cell Immunomics Approach. Immunological Reviews, 284, 120-131. [Google Scholar] [CrossRef] [PubMed]
[20] Fillatreau, S., Manfroi, B. and Dörner, T. (2020) Toll-Like Receptor Signalling in B Cells during Systemic Lupus Erythematosus. Nature Reviews Rheumatology, 17, 98-108. [Google Scholar] [CrossRef] [PubMed]
[21] Loftus, S.N., Liu, J., Berthier, C.C., Gudjonsson, J.E., Gharaee-Kermani, M., Tsoi, L.C., et al. (2023) Loss of Interleukin-1 Beta Is Not Protective in the Lupus-Prone NZM2328 Mouse Model. Frontiers in Immunology, 14, Article ID: 1162799. [Google Scholar] [CrossRef] [PubMed]
[22] Tilstra, J.S., Kim, M., Gordon, R.A., Leibler, C., Cosgrove, H.A., Bastacky, S., et al. (2023) B Cell-Intrinsic MyD88 Regulates Disease Progression in Murine Lupus. Journal of Experimental Medicine, 220, e20230263. [Google Scholar] [CrossRef] [PubMed]
[23] Teichmann, L.L., Schenten, D., Medzhitov, R., Kashgarian, M. and Shlomchik, M.J. (2013) Signals via the Adaptor MyD88 in B Cells and Dcs Make Distinct and Synergistic Contributions to Immune Activation and Tissue Damage in Lupus. Immunity, 38, 528-540. [Google Scholar] [CrossRef] [PubMed]
[24] Liao, Z., Yang, X., He, L., Bai, J., Zhou, X., Yang, J., et al. (2024) Cordyceps Protein Alleviates Renal Injury by Inhibiting T Cell Infiltration and Th1 Cell Differentiation in Lupus Nephritis Mice. International Immunopharmacology, 138, Article ID: 112566. [Google Scholar] [CrossRef] [PubMed]
[25] Reynolds, J.M. and Dong, C. (2013) Toll-Like Receptor Regulation of Effector T Lymphocyte Function. Trends in Immunology, 34, 511-519. [Google Scholar] [CrossRef] [PubMed]
[26] Li, B., Wang, M., Chen, S., Li, M., Zeng, J., Wu, S., et al. (2022) Baicalin Mitigates the Neuroinflammation through the TLR4/MyD88/NF-κB and MAPK Pathways in LPS-Stimulated BV-2 Microglia. BioMed Research International, 2022, Article ID: 3263446. [Google Scholar] [CrossRef] [PubMed]
[27] Ciesielska, A., Matyjek, M. and Kwiatkowska, K. (2020) TLR4 and CD14 Trafficking and Its Influence on LPS-Induced Pro-Inflammatory Signaling. Cellular and Molecular Life Sciences, 78, 1233-1261. [Google Scholar] [CrossRef] [PubMed]
[28] Li, J., Yang, Y., Wang, H., Ma, D., Wang, H., Chu, L., et al. (2022) Baicalein Ameliorates Myocardial Ischemia through Reduction of Oxidative Stress, Inflammation and Apoptosis via TLR4/MyD88/MAPK(S)/NF-κB Pathway and Regulation of Ca2+ Homeostasis by L-Type Ca2+ Channels. Frontiers in Pharmacology, 13, Article ID: 842723. [Google Scholar] [CrossRef] [PubMed]
[29] Dima, A., Jurcut, C., Chasset, F., Felten, R. and Arnaud, L. (2022) Hydroxychloroquine in Systemic Lupus Erythematosus: Overview of Current Knowledge. Therapeutic Advances in Musculoskeletal Disease, 14, 1-25. [Google Scholar] [CrossRef] [PubMed]
[30] Tsakonas, E., Joseph, L., Esdaile, J.M., Choquette, D., Senécal, J., Cividino, A., et al. (1998) A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus. Lupus, 7, 80-85. [Google Scholar] [CrossRef] [PubMed]
[31] Römmler, F., Jurk, M., Uhlmann, E., Hammel, M., Waldhuber, A., Pfeiffer, L., et al. (2013) Guanine Modification of Inhibitory Oligonucleotides Potentiates Their Suppressive Function. The Journal of Immunology, 191, 3240-3253. [Google Scholar] [CrossRef] [PubMed]
[32] Wang, J. and Gan, M. (2022) DNA Nanoflowers’ Amelioration of Lupus Symptoms in Mice via Blockade of TLR7/9’s Signal. International Journal of Molecular Sciences, 23, Article No. 16030. [Google Scholar] [CrossRef] [PubMed]
[33] Vlach, J., Bender, A.T., Przetak, M., Pereira, A., Deshpande, A., Johnson, T.L., et al. (2020) Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity. Journal of Pharmacology and Experimental Therapeutics, 376, 397-409. [Google Scholar] [CrossRef] [PubMed]
[34] Tanaka, Y., Tago, F., Yamakawa, N., Aoki, M., Yagi, T. and Akira, S. (2023) A New Therapeutic Target for Systemic Lupus Erythematosus: The Current Landscape for Drug Development of a Toll-Like Receptor 7/8 Antagonist through Academia-Industry-Government Collaboration. Immunological Medicine, 47, 24-29. [Google Scholar] [CrossRef] [PubMed]
[35] He, Y., Tian, W., Zhang, M., Qiu, H., Li, H., Shi, X., et al. (2023) Jieduquyuziyin Prescription Alleviates SLE Complicated by Atherosclerosis via Promoting Cholesterol Efflux and Suppressing TLR9/MyD88 Activation. Journal of Ethnopharmacology, 309, Article ID: 116283. [Google Scholar] [CrossRef] [PubMed]
[36] Olson, M.A., Lee, M.S., Kissner, T.L., Alam, S., Waugh, D.S. and Saikh, K.U. (2015) Discovery of Small Molecule Inhibitors of MyD88-Dependent Signaling Pathways Using a Computational Screen. Scientific Reports, 5, Article No. 14246. [Google Scholar] [CrossRef] [PubMed]
[37] Zou, Z., Du, D., Miao, Y., Yang, Y., Xie, Y., Li, Z., et al. (2020) TJ-M2010-5, a Novel MyD88 Inhibitor, Corrects R848-Induced Lupus-Like Immune Disorders of B Cells in Vitro. International Immunopharmacology, 85, Article ID: 106648. [Google Scholar] [CrossRef] [PubMed]
[38] Zheng, X., Sun, C., Liu, Q., Lu, X., Fu, L., Liang, G., et al. (2020) Compound LM9, a Novel MyD88 Inhibitor, Efficiently Mitigates Inflammatory Responses and Fibrosis in Obesity-Induced Cardiomyopathy. Acta Pharmacologica Sinica, 41, 1093-1101. [Google Scholar] [CrossRef] [PubMed]
[39] Song, J., Chen, D., Pan, Y., Shi, X., Liu, Q., Lu, X., et al. (2021) Discovery of a Novel MyD88 Inhibitor M20 and Its Protection against Sepsis-Mediated Acute Lung Injury. Frontiers in Pharmacology, 12, Article ID: 775117. [Google Scholar] [CrossRef] [PubMed]